Arrowhead Research reported $-1.26 in EPS Earnings Per Share for its fiscal quarter ending in June of 2025.


Fiscal Calendar Actual Consensus Previous Date
FY2025Q3 Jun/2025 -1.26 -0.86 -1.38 Aug/07 2025
FY2025Q2 Mar/2025 2.75 -0.11 -1.02 May/12 2025
FY2025Q1 Dec/2024 -1.39 -0.39 -1.24 Feb/10 2025
FY2024Q4 Sep/2024 -1.36 -0.97 -1.92 Nov/26 2024
FY2024Q3 Jun/2024 -1.38 -0.53 -0.96 Aug/08 2024


Financials
Assets USD 1.38B
Current Assets USD 946.92M
Debt USD 388.24M
EBIT USD -165.55M
EBITDA USD -159.33M
Interest Income USD 9.62M
Loan Capital USD 200.33M
Net Income USD -175.24M
Operating Expenses USD 193.32M
Operating Profit USD -165.55M
Pre-Tax Profit USD -179.09M
Sales Revenues USD 27.77M
Stock USD -173.09M
Trade Creditors USD 33.05M
Trade Debtors USD 9.7M

Eps Change Date
Agios Pharmaceuticals USD -1.93 0.38 Jun/2025
Alnylam Pharmaceuticals USD 0.32 0.33 Jun/2025
Arrowhead Research USD -1.26 4.01 Jun/2025
Incyte USD 1.57 0.41 Jun/2025
Ionis Pharmaceuticals USD 0.7 1.63 Jun/2025
Ligand Pharmaceuticals USD 1.6 0.27 Jun/2025
Merck USD 2.13 0.09 Jun/2025
Moderna USD -2.13 0.39 Jun/2025
Novartis USD 2.42 0.14 Jun/2025
Sarepta Therapeutics USD 2.02 5.44 Jun/2025
TG Therapeutics USD 0.17 0.14 Jun/2025
Ultragenyx Pharmaceutical USD -1.17 0.4 Jun/2025
Vertex Pharmaceuticals USD 4.52 0.46 Jun/2025
Xencor USD -0.41 0.25 Jun/2025